- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04929483
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH) (ENLIVEN)
February 9, 2024 updated by: 89bio, Inc.
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BIO89-100 in Subjects With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
This is a randomized, double-blind, placebo-controlled study that will evaluate the safety, efficacy, tolerability of BIO89-100 in patients with biopsy-confirmed fibrosis stages F2-F3 NASH.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
222
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
San Juan, Puerto Rico, 00927
- 89bio Clinical Study Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- 89bio Clinical Study Site
-
Birmingham, Alabama, United States, 35211
- 89bio Clinical Study Site
-
Dothan, Alabama, United States, 36305
- 89bio Clinical Study Site
-
Guntersville, Alabama, United States, 35976
- 89bio Clinical Study Site
-
Madison, Alabama, United States, 35758
- 89bio Clinical Study Site
-
-
Arizona
-
Chandler, Arizona, United States, 85224
- 89bio Clinical Study Site
-
Glendale, Arizona, United States, 85036
- 89bio Clinical Study Site
-
Peoria, Arizona, United States, 85306
- 89bio Clinical Study Site
-
Tucson, Arizona, United States, 85712-4044
- 89bio Clinical Study Site
-
Tucson, Arizona, United States, 85712-4046
- 89bio Clinical Study Site
-
Tucson, Arizona, United States, 85741
- 89bio Clinical Study Site
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205-6414
- 89bio Clinical Study Site
-
Little Rock, Arkansas, United States, 72205
- 89bio Clinical Study Site
-
-
California
-
Chula Vista, California, United States, 91911
- 89bio Clinical Study Site
-
Huntington Park, California, United States, 90255
- 89bio Clinical Study Site
-
Long Beach, California, United States, 90808
- 89bio Clinical Study Site
-
Orange, California, United States, 92866
- 89bio Clinical Study Site
-
Panorama City, California, United States, 91402
- 89bio Clinical Study Site
-
Rialto, California, United States, 92377
- 89bio Clinical Study Site
-
Santa Ana, California, United States, 92704
- 89bio Clinical Study Site
-
-
Colorado
-
Englewood, Colorado, United States, 80113
- 89bio Clinical Study Site
-
-
Florida
-
Boynton Beach, Florida, United States, 33472
- 89bio Clinical Study Site
-
Bradenton, Florida, United States, 34208
- 89bio Clinical Study Site
-
Fort Myers, Florida, United States, 33912
- 89bio Clinical Study Site
-
Lakeland, Florida, United States, 33805
- 89bio Clinical Study Site
-
Maitland, Florida, United States, 32127
- 89bio Clinical Study Site
-
Miami, Florida, United States, 33014
- 89bio Clinical Study Site
-
Miami, Florida, United States, 33147
- 89bio Clinical Study Site
-
Miami, Florida, United States, 33157
- 89bio Clinical Study Site
-
Miami Lakes, Florida, United States, 33016
- 89bio Clinical Study Site
-
Ocala, Florida, United States, 34471
- 89bio Clinical Study Site
-
Palmetto Bay, Florida, United States, 33157
- 89bio Clinical Study Site
-
Pinellas Park, Florida, United States, 33781
- 89bio Clinical Study Site
-
Port Orange, Florida, United States, 32127
- 89bio Clinical Study Site
-
Sarasota, Florida, United States, 34240
- 89bio Clinical Study Site
-
Viera, Florida, United States, 32940
- 89bio Clinical Study Site
-
-
Georgia
-
Athens, Georgia, United States, 30607
- 89bio Clinical Study Site
-
Sandy Springs, Georgia, United States, 30328
- 89bio Clinical Study Site
-
-
Indiana
-
New Albany, Indiana, United States, 47150
- 89bio Clinical Study Site
-
South Bend, Indiana, United States, 46635
- 89bio Clinical Study Site
-
-
Iowa
-
Iowa City, Iowa, United States, 52246
- 89bio Clinical Study Site
-
-
Kansas
-
Topeka, Kansas, United States, 66606
- 89bio Clinical Study Site
-
-
Louisiana
-
Marrero, Louisiana, United States, 70072-3151
- 89bio Clinical Study Site
-
Marrero, Louisiana, United States, 70072-3155
- 89bio Clinical Study Site
-
Monroe, Louisiana, United States, 71201
- 89bio Clinical Study Site
-
Shreveport, Louisiana, United States, 71103
- 89bio Clinical Study Site
-
-
Maryland
-
Glen Burnie, Maryland, United States, 21061
- 89bio Clinical Study Site
-
Greenbelt, Maryland, United States, 20770
- 89bio Clinical Study Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63033
- 89bio Clinical Study Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89119
- 89bio Clinical Study Site
-
Las Vegas, Nevada, United States, 89121
- 89bio Clinical Study Site
-
-
New Jersey
-
Florham Park, New Jersey, United States, 07932
- 89bio Clinical Study Site
-
-
New York
-
New York, New York, United States, 10033
- 89bio Clinical Study Site
-
-
North Carolina
-
Concord, North Carolina, United States, 28027
- 89bio Clinical Study Site
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- 89bio Clinical Study Site
-
Dayton, Ohio, United States, 45414
- 89bio Clinical Study Site
-
Springboro, Ohio, United States, 45066
- 89bio Clinical Study Site
-
Westlake, Ohio, United States, 44145
- 89bio Clinical Study Site
-
-
South Carolina
-
Greenwood, South Carolina, United States, 29646
- 89bio Clinical Study Site
-
Summerville, South Carolina, United States, 29485
- 89bio Clinical Study Site
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37421
- 89bio Clinical Study Site
-
Chattanooga, Tennessee, United States, 37411
- 89bio Clinical Study Site
-
Hermitage, Tennessee, United States, 37076
- 89bio Clinical Study Site
-
-
Texas
-
Austin, Texas, United States, 78757-8051
- 89bio Clinical Study Site
-
Austin, Texas, United States, 78757-8059
- 89bio Clinical Study Site
-
Beaumont, Texas, United States, 77702
- 89bio Clinical Study Site
-
Dallas, Texas, United States, 75234
- 89bio Clinical Study Site
-
Dallas, Texas, United States, 75246
- 89bio Clinical Study Site
-
Edinburg, Texas, United States, 78539
- 89bio Clinical Study Site
-
Fort Worth, Texas, United States, 76104
- 89bio Clinical Study Site
-
Garland, Texas, United States, 75044
- 89bio Clinical Study Site
-
Houston, Texas, United States, 77030
- 89bio Clinical Study Site
-
Houston, Texas, United States, 77099
- 89bio Clinical Study Site
-
San Antonio, Texas, United States, 78215
- 89bio Clinical Study Site
-
San Antonio, Texas, United States, 78209
- 89bio Clinical Study Site
-
San Antonio, Texas, United States, 78229-4801
- 89bio Clinical Study Site
-
San Antonio, Texas, United States, 78229-5069
- 89bio Clinical Study Site
-
Waco, Texas, United States, 76710
- 89bio Clinical Study Site
-
Waco, Texas, United States, 76712
- 89bio Clinical Study Site
-
Wichita Falls, Texas, United States, 76301
- 89bio Clinical Study Site
-
-
Utah
-
Ogden, Utah, United States, 84405
- 89bio Clinical Study Site
-
Sandy, Utah, United States, 84092
- 89bio Clinical Study Site
-
-
Virginia
-
Manassas, Virginia, United States, 20110
- 89bio Clinical Study Site
-
Richmond, Virginia, United States, 23235
- 89bio Clinical Study Site
-
Richmond, Virginia, United States, 23249
- 89bio Clinical Study Site
-
Roanoke, Virginia, United States, 24014
- 89bio Clinical Study Site
-
-
Washington
-
Seattle, Washington, United States, 98105
- 89bio Clinical Study Site
-
Spokane, Washington, United States, 99202
- 89bio Clinical Study Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Age 21 to 75
Biopsy-confirmed NASH with fibrosis stage F2 or F3 per NASH CRN System and NAS ≥4, with a score of at least 1 in each of steatosis, ballooning degeneration, and lobular inflammation.
- Qualifying biopsy must be either within 6 months of screening visit or obtained during screening period
Key Exclusion Criteria:
- Have poorly controlled high blood pressure
- Have type 1 diabetes or poorly controlled type 2 diabetes.
- History of cirrhosis or evidence of cirrhosis by clinical, imaging or liver biopsy evaluation
- Are planning to try to lose weight during the conduct of the study.
- Have a BMI <25 kg/m2
Other inclusion and exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BIO89-100 - 15 mg QW
|
Subcutaneous injection
|
Experimental: Experimental: BIO89-100 - 30 mg QW
|
Subcutaneous injection
|
Experimental: Experimental: BIO89-100 - 44 mg Q2W
|
Subcutaneous injection
|
Placebo Comparator: Placebo Comparator: Placebo QW
|
Subcutaneous injection
|
Placebo Comparator: Placebo Comparator: Placebo Q2W
|
Subcutaneous injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Main: Proportion of participants with histological resolution of NASH without worsening of fibrosis
Time Frame: 24 Weeks
|
24 Weeks
|
Main: Proportion of participants with ≥1 stage decrease in fibrosis stage with no worsening of NASH
Time Frame: 24 Weeks
|
24 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Main: Proportion of participants with at least a 2-point improvement in NAS and no worsening of fibrosis
Time Frame: 24 Weeks
|
24 Weeks
|
|
Main: Proportion of participants with NASH resolution AND with ≥1 stage decrease in fibrosis stage
Time Frame: 24 Weeks
|
24 Weeks
|
|
Main: Proportion of participants with at least a 2-point improvement in NAS and are MRI-PDFF responders AND ALT responders
Time Frame: 24 Weeks
|
24 Weeks
|
|
Main: Absolute and percentage change from baseline in serum triglycerides
Time Frame: 12 Weeks, 24 Weeks
|
12 Weeks, 24 Weeks
|
|
Main: Absolute and percentage change from baseline in Low Density Lipoprotein (LDL) Cholesterol
Time Frame: 12 Weeks, 24 Weeks
|
12 Weeks, 24 Weeks
|
|
Main: Absolute change and percentage change from baseline in Alanine Transaminase (ALT)
Time Frame: 12 Weeks, 24 Weeks, 48 Weeks
|
12 Weeks, 24 Weeks, 48 Weeks
|
|
Main: Absolute change and percentage change from baseline in N-terminal type III collagen propeptide (Pro-C3)
Time Frame: 12 Weeks, 24 Weeks, 48 Weeks
|
12 Weeks, 24 Weeks, 48 Weeks
|
|
Main: Absolute change and percentage change from baseline in Magnetic Resonance Imaging - Hepatic Fat Fraction (MRI-PDFF)
Time Frame: 12 Weeks, 24 Weeks, 48 Weeks
|
12 Weeks, 24 Weeks, 48 Weeks
|
|
Main: Percentage change from baseline in HbA1c
Time Frame: 12 Weeks, 24 Weeks
|
12 Weeks, 24 Weeks
|
|
Main: Absolute and percentage change from baseline in Adiponectin
Time Frame: 12 Weeks, 24 Weeks
|
12 Weeks, 24 Weeks
|
|
Main: Steady-state blood level of BIO89-100
Time Frame: Blood samples for PK analysis collected at up to 8 study visits over the course of approximately 48 weeks
|
Plasma trough concentration (ng/mL) of BIO89-100 taken at pre-dose samples
|
Blood samples for PK analysis collected at up to 8 study visits over the course of approximately 48 weeks
|
Main: Absolute and percentage change from baseline in Non High Density Lipoprotein (HDL) Cholesterol
Time Frame: 12 Weeks, 24 Weeks
|
12 Weeks, 24 Weeks
|
|
Main: Absolute and percentage change from baseline in High Density Lipoprotein (HDL) Cholesterol
Time Frame: 12 Weeks, 24 Weeks
|
12 Weeks, 24 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Millie Gottwald, PharmD, 89bio, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 4, 2021
Primary Completion (Actual)
February 14, 2023
Study Completion (Estimated)
September 1, 2024
Study Registration Dates
First Submitted
June 10, 2021
First Submitted That Met QC Criteria
June 10, 2021
First Posted (Actual)
June 18, 2021
Study Record Updates
Last Update Posted (Estimated)
February 13, 2024
Last Update Submitted That Met QC Criteria
February 9, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BIO89-100-122
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NASH - Nonalcoholic Steatohepatitis
-
Milton S. Hershey Medical CenterRecruitingExercise | NASH - Nonalcoholic Steatohepatitis | NASH | LiverUnited States
-
Polaris GroupNot yet recruiting
-
Corcept TherapeuticsRecruitingNonalcoholic Steatohepatitis (NASH)United States
-
PerspectumRecruitingNASH - Nonalcoholic SteatohepatitisUnited States
-
Metacrine, Inc.Completed
-
Cascade Pharmaceuticals, IncLaboratory Corporation of AmericaCompletedNonalcoholic Steatohepatitis (NASH)United States
-
Poxel SACompletedNASH - Nonalcoholic SteatohepatitisUnited States
-
RWTH Aachen UniversityCompletedNASH - Nonalcoholic SteatohepatitisSweden, Austria, Germany
-
CymaBay Therapeutics, Inc.TerminatedNASH - Nonalcoholic SteatohepatitisUnited States
-
Akero Therapeutics, IncCompletedNASH - Nonalcoholic SteatohepatitisUnited States, Puerto Rico
Clinical Trials on BIO89-100
-
89bio, Inc.CompletedNASH - Nonalcoholic SteatohepatitisUnited States
-
89bio, Inc.ProSciento, Inc.CompletedNASHUnited States, Puerto Rico
-
89bio, Inc.RecruitingMetabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With FibrosisUnited States
-
89bio, Inc.CompletedSevere HypertriglyceridemiaUnited States, Czechia, Hungary, Poland
-
OrthoTrophix, IncCompleted
-
Wageningen UniversityFriesland CampinaUnknownNutrition | Metabolism | Genomics | Postprandial MetabolismNetherlands
-
San Diego State UniversityCompleted
-
Sumitomo Pharma America, Inc.BehaVR LLCCompletedSocial Anxiety Disorder (SAD)United States
-
ShireCompletedAcute Viral ConjunctivitisUnited States, Brazil
-
ExThera Medical CorporationCompletedBacteremia | Bacterial InfectionGermany